Vera Therapeutics (VERA) has released an update.
Effective January 29, 2024, the Company halted its at-the-market offering of Class A common stock and terminated the associated prospectus under the 2022 Sales Agreement with Cowen and Company, LLC. The agreement remains in effect, but no stock sales will occur until a new prospectus or registration is filed. The company’s current report includes forward-looking statements about its financial estimates, which are speculative and subject to change due to inherent risks and uncertainties.
For further insights into VERA stock, check out TipRanks’ Stock Analysis page.
